Robotic-arm Assisted Ga-68 PSMA PET/CT Guided Transgluteal Prostate Biopsy
NCT05022576 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 78
Last updated 2021-08-26
Summary
Gallium-68 prostate-specific-membrane-antigen (Ga-68 PSMA) PET/CT is being used in Prostate cancer imaging. In the present study, we aimed to evaluate the efficacy and safety of robotic arm-assisted Ga-68 PSMA PET/CT-guided transgluteal prostatic biopsy.
Seventy-eight participants with a clinical suspicion of PCa were recruited from January 2019 to September 2020. All the patients underwent whole-body Ga-68 PSMA PET/CT. The patients with PSMA-avid lesion in the prostate underwent robotic arm-assisted PET-guided transgluteal biopsies. The degree of pain during the procedure, procedure-related complications and histopathology were evaluated.
Conditions
Interventions
- DIAGNOSTIC_TEST
-
Robotic arm assisted PSMA PET/CT guided prostate biopsy
The patients were positioned prone on PET/CT table. The regional PET/CT image of the lower pelvic region were acquired for the procedure. The images were transferred to the ROBIO™ EX workstation. The ARA workstation determined the needle trajectory, depth of the lesion and angulations. The planned trajectory was appraised for its relationship with the vital organs. Strict surgical aseptic approach was followed for the procedure under local anesthesia. An 18G x 20cm coaxial system was manually introduced through the bush and pushed with the help of robotic arm through the gluteal skin entry site to the predetermined depth in the prostate. The real-time placement of the needle was confirmed with low dose CT and the biopsy specimens were retrieved. After the procedure, patient vitals and any difficulty in micturition were observed for two hours in the recovery area. The specimens were sent for histopathological examination.
Sponsors & Collaborators
-
Post Graduate Institute of Medical Education and Research, Chandigarh
lead OTHER
Study Design
- Allocation
- NA
- Purpose
- DIAGNOSTIC
- Masking
- NONE
- Model
- SINGLE_GROUP
Eligibility
- Sex
- MALE
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2019-01-30
- Primary Completion
- 2020-09-30
- Completion
- 2020-09-30
Countries
- India
Study Locations
More Related Trials
-
68Ga-PSMA-11 PET/CT Screening Prior to 177Lu-PSMA-617 Therapy for Patients With Metastatic Castrate Resistant Prostate Cancer
NCT05547386 ·Status: COMPLETED ·Phase: PHASE3
-
Gallium-68 PSMA-11 PET in Intermediate to High-risk Preprostatectomy Patients
NCT02919111 ·Status: COMPLETED ·Phase: PHASE2/PHASE3
-
68Ga PSMA 11 PET/MRI and 68Ga RM2 PET/MRI for Biopsy Guidance in Patients With Suspected Prostate Cancer
NCT03809078 ·Status: COMPLETED ·Phase: PHASE2
-
Gallium-68 PSMA-11 PET Imaging in Prostate Cancer Patients
NCT03803475 ·Status: COMPLETED ·Phase: PHASE3
-
68Ga-PSMA-11 PET for the Diagnosis of Biochemically Recurrent Prostate Cancer
NCT04216134 ·Status: COMPLETED ·Phase: PHASE1
-
Pharmacokinetics of IA and IV Ga68-PSMA-11 Infusion
NCT04976257 ·Status: COMPLETED ·Phase: EARLY_PHASE1
-
Evaluation of Gallium-68-HBED-CC-PSMA Imaging in Prostate Cancer Patients
NCT02611882 ·Status: COMPLETED ·Phase: PHASE2
-
68Ga PSMA in Preprostatectomy Patients
NCT03388346 ·Status: COMPLETED ·Phase: PHASE2/PHASE3
-
PSMA Specific [68Ga]-P137 Peptide Probe for PET Imaging in Prostate Cancer
NCT04560725 ·Status: ACTIVE_NOT_RECRUITING ·Phase: NA
-
68Ga-PSMA PET/CT Imaging in Assessment of Prostate Cancer
NCT05134064 ·Status: COMPLETED
-
Gallium-68 PSMA-11 Positron Emission Tomography (PET) Imaging in Patients With Biochemical Recurrence
NCT03353740 ·Status: COMPLETED ·Phase: PHASE3
-
Research on the Application of 68Ga-PSMA-CYC PET Imaging in the Diagnosis, Staging, and Restaging of Prostate Cancer
NCT07056790 ·Status: RECRUITING ·Phase: PHASE1/PHASE2
-
Multicenter Randomized Trial of 68Ga-PSMA-11 PET/CT Based SRT After Radical Prostatectomy
NCT03582774 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE3
-
Positron Emission Tomography / Magnetic Resonance Imaging (PET/MRI) Guided Biopsy in Men With Elevated PSA
NCT03187990 ·Status: COMPLETED ·Phase: NA
-
The Role of 68Gallium PSMA-11 in Enhancing Diagnosis of Primary and Metastatic Prostate Cancer
NCT04179968 ·Status: COMPLETED ·Phase: PHASE2
-
68Ga-PSMA-11 PET/MRI in Finding Tumors in Patients With Intermediate or High-Risk Prostate Cancer Undergoing Surgery
NCT02678351 ·Status: COMPLETED ·Phase: PHASE2/PHASE3
-
68Ga-P3 PET/CT Imaging in Malignancy
NCT05887687 ·Status: RECRUITING ·Phase: NA
-
Ex-vivo Investigation of Beta Probe for Prostate Cancer Resection and Evaluation of PSMA-PET for Diagnosis of Intraprostatic Lesions
NCT03213951 ·Status: COMPLETED
-
Clinical Use of 68Ga PSMA-11 PET/CT in Diagnosing, Staging and Restaging Prostate Cancer
NCT05002465 ·Status: NO_LONGER_AVAILABLE
-
Radiolabeled Gallium-68 (68Ga-PSMA) for PET/CT Imaging to Detect Prostate Cancer
NCT03689582 ·Status: TERMINATED ·Phase: PHASE2
-
The Value of PSMA-PET Compared With Multi-parametric MRI in the Detection Prostate Lesions
NCT03174054 ·Status: UNKNOWN
-
68Ga-NOTA-RM26 PET/CT in Prostate Cancer Patients
NCT03164837 ·Status: UNKNOWN ·Phase: PHASE1
-
The Role of Ga68-PSMA-11 PET Imaging in Prostate Cancer Patients Undergoing Androgen Deprivation Therapy
NCT03977610 ·Status: COMPLETED ·Phase: NA
-
68Ga-THP-PSMA PET/CT in Prostate Cancer: Clinical Stage and Restage
NCT04158817 ·Status: COMPLETED ·Phase: EARLY_PHASE1
-
A Study of 68Ga-GRP PET/CT for Imaging in Low and Intermediate Risk Prostate Cancer
NCT05073653 ·Status: UNKNOWN ·Phase: NA